Expertise in
8
conditions

Thomas S. Larsen

Søndre Boulevard 29, 
Odense, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Søndre Boulevard 29, 
Odense, DK 

Overview

Thomas Larsen practices practicing medicine in Odense, Denmark.

Mr. Larsen is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Polycythemia Vera, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Søndre Boulevard 29, Odense, 5000, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: R-pola-mini-CHP, R-mini-CHOP
Study Phase: Phase 3
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Rituximab, Methotrexate, Procarbazine, Lenalidomide, Temozolomide
Study Phase: Phase 2
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Combination product
Study Drugs: R-CHOEP, DA-EPOCH-R
Study Phase: Phase 2
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Enrollment Status: Unknown
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

98 Total Publications

A real-world comparison of CD20xCD3 bispecific antibodies versus chemotherapy regimens in 3+ line relapsed/refractory diffuse large B cell lymphoma.
A real-world comparison of CD20xCD3 bispecific antibodies versus chemotherapy regimens in 3+ line relapsed/refractory diffuse large B cell lymphoma.
Journal: Leukemia & lymphoma
Published: March 11, 2026

Frequently Asked Questions about Thomas S. Larsen

Is Thomas S. Larsen a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas S. Larsen is classified as an Elite expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas S. Larsen participate in research or clinical trials?

Yes. Thomas S. Larsen has published 98 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Thomas S. Larsen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Larsen's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile